EU opens rare excessive pricing investigation
The European Commission has opened a formal investigation into Aspen following concerns that the drugmaker has unjustifiably increased the price of several anti-cancer medications, marking the enforcer’s first excessive pricing case in the pharmaceutical sector.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.